Prescriptions for antipsychotic medication grew by 10% in 2010
Abilify, Zyprexa and Seroquel led the growth of second generation anti-psychotics led spending growth with a combined $1.4 billion. Download the entire report from the IMS, Institute for Health Care Informatics. ... []
Eli Lilly: CEO gets raise, more Zyprexa law suits settled
Eli Lilly joins the list of companies with CEO's earning hefty compensation this year. John Lechleiter's earning package for 2009 was reported at $20.9 million, . . . []
FDA cautions Zyprexa for teens
Metabolic side effects will become standard black box warnings for adolescents taking olanzapine (Zyprexa) as a result of an FDA ruling. The new guidelines. . . []
Lilly beats back Mississippi over Zyprexa
A US District Court judge dismissed use of a statistical summary to prove Zyprexa's side effects boost Medicaid costs in Mississippi. []
Lilly settles
Eli Lilly and the Department of Justice reached a series of settlements resulting from illegal marketing, defrauding the government, and making false claims related to Zyprexa. The company will pay more than $1.4 billion (including a criminal fine of $515 million) for a scheme that broadly affected patient health, government spending and the credibility of federal regulatory agencies. A five-year corporate integrity agreement specifying reporting, written standards, and tracking of information, was part of the settlement. ... []
Lilly takes $1.4 billion charge for law suits
Five years after investigations into Eli Lilly's marketing of Zyprexa, the company announced settlement talks of $1.4 billion relating to "past U.S. marketing and promotional practices." Lilly previously agreed to settlements with individual plaintiffs and 33 states for charges of deceptive marketing leading to Medicaid expenses and life-threatening side effects. The "Medicaid fraud control units of more than 30 states are coordinating with federal prosecutors," reports the New York Times. ... []
Antipsychotic meds and heart disease
An NIMH study (n=1125) comparing antipsychotic medications and cardiac heart disease found the "risk for CHD differed significantly among the medications." Risk, marked by elevated cholesterol, was highest for those taking olanzapine (Zyprexa, Zydis) and quetiapine (Seroquel). A decreased risk was noted for those taking risperidone (Risperdal) and ziprasidone (Geodon). Cardiovascular disease is a contributing factor to the shorter life span of people diagnosed with schizophrenia.... []
Eli Lilly settles $62 million case; more pending
Eli Lilly announced a $62 million settlement in 32 states for the marketing of its block buster drug Zyprexa. In the 12 years it has been on the market, the company says it has been prescribed 26 million times. Zyprexa is known to cause weight gain leading to diabetes, heart disease, both of which are associated with early death. Other law suits are still outstanding. Since 2005, according to SEC filings, costs associated with Zyprexa lawsuits, including legal fees, amount... []
Lilly agrees to disclose
Zyprexa maker Eli Lilly has agreed to public disclosure of fees it pays physicians who endorse or educate about their products. Lilly is the first pharmaceutical to announce it would disclose even if the Physicians Payments Sunshine Act (H.R. 5605) did not become law. According to a company statement: the public will have access to an Internet database listing its payments to physicians. Lilly will launch this registry as early as the second half of 2009. When first launched, its... []
New drugs more costly, more side effects, not better
The newer classification of drugs (Zyprexa, Risperdal, Geodone) commonly prescribed for schizophrenia, as well as bipolar disorders and behavioral management for children and teenagers have been found to be no more effective than the older drugs, according to an article published in the American Journal of Psychiatry. Studies of adults have led to similar findings which could challenge the record profits of drug companies that have recently obtained additional applications for treating children. reports that generics are already denting... []
Zyprexa documents unsealed
The judge in last year's law suit over Eli Lilly's drug Zyprexa ordered the documents unsealed in what he termed a class-action law suit. According to the New York Times, Judge Jack B. Weinstein weighed Lilly's rights to privacy against the public's right to know how the drug was marketed and approved. A New York Times reporter was reprimanded last year after writing about company decisions based on documents that eventually were circulated widely on the internet. Weinstein's actions followed... []
Drugs in pipeline
What's in an FDA approval
FDA approval, watchdogs and court cases: what this means for you []
Alasks settles Zyprexa case
Eli Lilly has agreed to a $15 million settlement with Alaska over the drug Zyprexa, used a drug to treat schizohprenia and bipolar disorder. The settlement ended a jury trial which began March 6 in Anchorage Superior Court, in which Alaska asked for $270 million for the drug used in its Medicaid program. Reuters reports that Conn. brought a similar law suit on March 11. The company has paid out more than $1.2 billion to settle 30,000 individual law suits.... []
Zyprexa off-label
Off-label use of Zyprexa to treat disruptive children or address pain was aired in an Anchorage courtroom last week. A previously undisclosed 2003 memo from John C. Lechleiter, who will become CEO in April, said “to seize the opportunity to expand our work with Zyprexa” by using the door it had opened with pediatricians about another medication. The company says it was only trying to respond to physician interest. Alaska is suing Eli Lilly to recoup Medicaid costs for treating... []
Zyprexa trial in Alaska
Alaska is the first of nine states to sue Eli Lilly, manufacturer of Zyprexa, in a case that has wide ranging implications. Allegations that the company hid information about adverse side effects, such as weight gain leading to diabetes and cardiac complications, have already led to individual settlements of $1 billion. The Alaska case opens a different door. It is the first to have a jury trial, and asks the company to be liable for state Medicaid expenses for people... []
Pharma influence grows
Pharms spends more on lobbying while we spend more on drugs. []
Zyprexa settlement rumored
Pharma giant Eli Lilly, maker of Zyprexa, is said to be in conversation with the federal government to pay $1 billion to settle charges over its promotional activities, reports the New York Times. Zyprexa is the company's block buster drug for schizophrenia and bipolar disorder, and last year accounted for $4.8 billion in sales, about one-quarter of Lilly’s revenue. In the past two years, the company has been hit by more than 25,000 claims for failure to warn about serious... []
Schizophrenia drug in pipeline
Enthusiasm greeted Eli Lilly's announcement that a drug to treat schizophrenia showed promising results - similar to Zyprexa but without the weight gain - in its initial stage of testing. This is considered the first major breakthrough in 50 years because it targets a different system of receptors which are triggered by an amino acid called glutamate, not the dopamine receptors. Work on glutamate receptors leading to this medicine emerged during the 1980s when scientists noted a street drug, PCP,... []
Debate continues over antipsychotics for kids
Last year's death of a four year-old in Boston, and concern over efficacy, have created a backlash about treating young children with atypical anti-psychotics. Sunday's Boston Globe report how child psychiatrists are lining up in the debate. In Mass., the number of children under the age of 18 who are receiving the most commonly prescribed drugs (Zyprexa, Risperdal, and Seroquel) increased 25 percent over a four year period ending in 2006.... []
Counterfeit drugs seized in the UK
Anxiety Insights, May 26, 2007 The United Kingdom has issued a drug alert about a counterfeit Zyprexa (10 mg), containing only 60 percent of the active ingredients of olanzapine. British authorities also issued a warning for, Plavix, prescribed for thinning blood. ... []
Issues / Advocacy
Action oriented non-profit groups with a national base promoting recovery, equity and social justice. []
Eli Lilly teams with states to monitor Zyprexa
The New York Times reports that in 20 states, Medicaid and Eli Lilly monitor how doctors are prescribing Zyprexa. Lilly pays for the service if states do not require doctors to seek permission for prescribing the medication. The company claims it helps keep costs down, helps patients receive proper dosages. Others say it is a marketing ploy involving rebates and preferred lists. Zyprexa, the most frequently prescribed drug for schizophrenia and bipolar disorder, can cost up to $300 a month.... []
AstraZeneca faces law suits similar to Eli Lilly’s
Bloomberg News reports that British pharmaceutical, AstraZeneca, maker of blockbuster Seroquel, faces lawsuits from 10,000 people alleging that the medicine caused weight gain leading to the risk of diabetes. Competitor Eli Lilly has been entangled in a similar charge over its drug Zyprexa. Last year Seroquel passed Zyprexa as the top selling atypical antipsychotic on the market, earning $3.4 billion, up from $66 million in 1998. As an explanation for the dramatic increase in market share, patients cited “aggressive marketing”... []

Phyllis Vine

Consider This

by Phyllis Vine

Relevant Sites

Featured Videos

Watch videos at Vodpod and politics videos and more of my videos

MIWatch Archives

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Search only trustworthy HONcode health websites:

Top 50 Wellness Guru Award
Accredited Online Colleges

Fatal error: Cannot redeclare is_valid_email() (previously declared in /home/miwatch/public_html/cgi-bin/mt/php/mt.php:825) in /home/miwatch/public_html/cgi-bin/mt/php/mt.php on line 831